ANN ARBOR, Mich., Oct. 16, 2025 – Peptinovo Biopharma, a biotechnology company
pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, today
announced a strategic manufacturing partnership with Ardena, a specialist pharmaceutical
contract development and manufacturing organization (CDMO) and bioanalytical contract
research organization (CRO) enabling precision medicines and other complex therapies. Ardena
will manufacture Peptinovo’s cancer drug-delivery nanotechnology for the company’s planned
launch of human clinical trials by year’s end
Securing an established manufacturing partner marks a critical milestone for Peptinovo. In the
pharmaceutical industry, manufacturing stability is essential to move breakthrough science
from the lab to patients, and Ardena’s expertise provides the assurance of scalability,
repeatability, and quality required for global clinical development.
“Partnering with Ardena is a huge step forward for Peptinovo because it demonstrates we have
achieved the level of manufacturing stability that is so vital in this industry,” Peptinovo
Biopharma CEO Steve Tokarz said. “Our team has developed a clever, innovative technology
that is designed to be both scalable and reproducible. To have accomplished this on a tight
timeline is an incredible validation of our platform as we prepare for our first human clinical
trials by the end of the year.”
Peptinovo’s proprietary PALM™ (Peptide-Assisted Lipid Micelle) technology is designed to
deliver chemotherapy agents more precisely to tumors, minimizing toxicity and maximizing
therapeutic effect. Ardena will leverage its established nanomedicine expertise, pharmaceutical
manufacturing and analytical capabilities, strong project management, and a proven record of
advancing nanoparticle-based medicines to clinical trials to support Peptinovo’s advancement
to clinical trials late this year in Australia.
“We are delighted to support Peptinovo’s innovative program,” Ardena COO Gerjan
Kemperman said. “Peptinovo’s technology holds great promise in advancing cancer treatment,
and our experience in nanomedicine manufacturing is a strong complement to the company’s
scientific platform. Together, we are striving to accelerate the development of precision
medicines, advancing scientific innovation into patient impact.”
About Peptinovo Biopharma
Peptinovo Biopharma is a privately held biotechnology company based in Ann Arbor, Michigan,
developing next-generation targeted nanomedicines to enhance cancer treatment. Its
proprietary PALM™ technology delivers proven chemotherapies directly to tumors while
reducing toxicity to healthy tissues, aiming to improve outcomes and quality of life for patients.
The company has raised $15.7 million to date and is raising additional funds in its current Series A
round to expand development of its platform
For more information, visit www.peptinovo.com .
About Ardena
Ardena is a specialist pharmaceutical Contract Development and Manufacturing Organization
(CDMO) and bioanalytical Contract Research Organization (CRO) dedicated to advancing
precision medicines. Its integrated solutions enable innovative and complex molecules through
services in nanomedicine, drug product and substance manufacturing, solid-state chemistry,
bioanalytical services, and CMC regulatory support.
Visit www.ardena.com for more information.
Peptinovo Media Contact
Katie Merx
katie@merxpr.com
+1 313.510.5090